Journal
JOURNAL OF VIROLOGY
Volume 85, Issue 21, Pages 11526-11531Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.05418-11
Keywords
-
Categories
Funding
- Pfizer
- NIH/NIAID [RO1 AI087145, K24AI069994, AI76059, AI84113]
- CFAR Network of Integrated Clinical Systems (CNICS) [1 R24 AI067039-1]
- UCSF Gladstone Institute of Virology & Immunology Center for AIDS Research (CFAR)
- NIH [P30 AI027763]
- Fogarty International Center [D43 TW00003]
- UCSF Clinical and Translational Science Institute [UL1 RR024131]
- American Foundation for AIDS Research [106710-40-RGRL]
- Ragon Institute, Boston, MA
Ask authors/readers for more resources
Human endogenous retrovirus (HERV)-specific T cell responses in HIV-1-infected adults have been reported. Whether HERV-specific immunity exists in vertically HIV-1-infected children is unknown. We performed a cross-sectional analysis of HERV-specific T cell responses in 42 vertically HIV-1-infected children. HERV (-H, -K, and -L family)-specific T cell responses were identified in 26 of 42 subjects, with the greatest magnitude observed for the responses to HERV-L. These HERV-specific T cell responses were inversely correlated with the HIV-1 plasma viral load and positively correlated with CD4(+) T cell counts. These data indicate that HERV-specific T cells may participate in controlling HIV-1 replication and that certain highly conserved HERV-derived proteins may serve as promising therapeutic vaccine targets in HIV-1-infected children.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available